Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Vascular Endothelial Cell Gene Expression Linked to Atherosclerosis and Other Inflammatory Diseases.
- Endothelial Cell Expression of Leukocyte Adhesion Molecules
- TNF Activation of the Endothelium
- Unni Chandrasekharan, PhD, Project Scientist
- Daniel Harris, PhD, Doctoral Student (CWRU Physiology)
- Chad Bradley, Technician
- Mohammad Rajabi, MD, PhD
- Paul Fox, PhD
- Thomas Egelhoff, PhD
- Xiaoxia Li, PhD
- Tatiana Byzova, PhD
- Sathyamangla Prasad, PhD
The central objective of our research is to understand the role of endothelial cell (EC) gene expression in the maintenance of healthy blood vessels and in the genesis of vascular diseases. We are pursuing the thrombin- and cytokine-activated intracellular signaling pathways and transcription factors responsible for induction of pro-inflammatory events, including leukocyte adhesion to EC, in vivo and in vitro. We are currently focused on the relative importance of the two tumor necrosis factor (TNF)-alpha receptors in EC activation and in such diseases as atherosclerosis and psoriasis. We are elucidating the specific signaling pathways triggered by each receptor that must combine to generate the inflammatory response. We are also studying the role of the homeobox transcription factor HOXA9 and its binding partner protein arginine methyl transferase 5 (PRMT5) in the induction of proinflammatory genes in EC. Finally, we are characterizing regulatory pathways involved in the expression of inflammatory genes and induction of angiogenesis by EC in response to the protease thrombin and the angiogenic factor VEGF and defining the induction and functions of the dual-specificity nuclear phosphatase MKP 1 (MAP kinase phosphatase-1). An overriding goal of the research program is to identify novel targets for anti-inflammation therapy.
endothelium, cell growth control, vascular cell interactions
American Association for the Advancement of Science
American Heart Association
- Fellow of the Council on Arteriosclerosis Executive Committee, 1992-1994
- Fellow of the Council on Arteriosclerosis, Thrombosis, and Vascular Biology, Program Committee, 1997-2001
- Spring Conference Chair, 2000-2001
- Executive Committee, 1998-2003
- Research Steering Committee, 2005-2009
American Society for Cell Biology
American Society of Investigative Pathology
- Program Committee, 1992-1997
- Nominating Committee, 1998-2000
American Society for Microbiology
North American Vascular Biology Organization
- Program Committee Chair, Council Member, 1995-2001
- President-Elect, 2001-2002
- President, 2002-2003
- Scientific Advisory Board, October 2007 to October 2012
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 4/1/2015, Dr. DiCorleto has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.